FindTrial
Sign In

Menjugate®

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline

Conditions

Acellular PertussisDiphtheriaDiphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria MeniHaemophilus Influenzae Type bHepatitis BInfections, MeningococcalMeningococcal VaccinesNeisseria Meningitidis

Phase 2

Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age
CompletedNCT00970307
GlaxoSmithKlineAcellular Pertussis, Diphtheria, Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meni +4
Start: 2009-08-13End: 2010-01-27Updated: 2020-01-03
Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants
CompletedNCT01090453
GlaxoSmithKlineAcellular Pertussis, Diphtheria, Haemophilus Influenzae Type b +4
Start: 2010-05-17End: 2011-10-11Updated: 2018-08-20

Phase 3

Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines
CompletedNCT01144663
GlaxoSmithKlineInfections, Meningococcal, Meningococcal Vaccines
Start: 2010-07-01End: 2013-09-10Updated: 2020-12-31

Related Papers

Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib and PHiD-CV When Coadministered With MenACWY-TT in Infants: Results of an Open, Randomized Trial.
2018-07-011 citations
Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants: An Open, Randomized Trial.
2017-04-0110 citations
A randomized study to evaluate the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, haemophilus influenzae b, and meningococcal serogroup C combination vaccine administered to infants at 2, 4 and 12 months of age.
2014-12-014 citations
A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12-18 months of age.
2013-07-016 citations